Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics
Bioventus Inc. Class A Common Stock · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · Now $7.93
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS